Benefits for Moderation and Abstinence Goals Reduction in Cravings and Alcohol Intake: GLP-1 agonists appear to attenuate reward responses to alcohol, making it easier for people to feel satisfied before they pass their off switch and drink more than intended
Strong evidence supports their efficacy in inducing clinically meaningful weight loss in individuals with overweight or obesity
Research indicates that the rs1967017 variant in PDZK1 creates a binding site for the transcription factor hepatocyte nuclear factor 4 (HNF4) within an enhancer region upstream of the PDZK1 transcription start site
At present, the Food and Drug Administration (FDA) has approved some anti-obesity drugs, including GLP-1RA liraglutide and semaglutide
Patient experiences show that cost, tolerability, lifestyle, and personal goals all influence whether they continue, taper, cycle, or stop altogether
In mouse fertility studies with exenatide, the active ingredient in BYDUREON, at twice-daily subcutaneous doses of 6, 68, or 760 mcg/kg/day, males were treated for 4 weeks prior to and throughout mating, and females were treated 2 weeks prior to mating and throughout mating until gestation day 7